LNA-based oligonucleotide electrotransfer for miRNA inhibition

Molecular Therapy

Volumn 20, Issue 8, 2012, Pages 1590-1598

  Chabot, Sophie ^a,b   Orio, Julie ^a,b   Castanier, Romain ^a,b   Bellard, Elisabeth ^a,b   Nielsen, Søren J ^c   Golzio, Muriel ^a,b   Teissié, Justin ^a,b  

^a INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c Exiqon AS   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; COMPLEMENTARY DNA; CYANINE DYE 5; LOCKED NUCLEIC ACID; MICRORNA; MICRORNA 34A;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE REGULATION; CELL NUCLEUS; CELL PERMEABILIZATION; CELL TRANSFER; CELL VIABILITY; CELLULAR DISTRIBUTION; CHEMICAL LABELING; CONTROLLED STUDY; CYTOPLASM VESICLE; ELECTROPHORETIC MOBILITY; ELECTROPORATION; FEMALE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE DELIVERY SYSTEM; GENE LOCATION; GENE TARGETING; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; OLIGOMERIZATION; PROCESS OPTIMIZATION; SINGLE CELL ANALYSIS;

EID: 84864571612     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.95     Document Type: Article

References (50)

1. Bartel, DP (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
2. Ambros, V (2001). microRNAs: tiny regulators with great potential. Cell 107: 823-826.
3. He L, Michael Thomson J, Hemann MT, Hernando-Monge E, Mu D, Goodson S et al. (2005). A microRN. A polycistron as a potential human oncogene. Nature 435: 828-833.
4. Stenvang J, Lindow M and Kauppinen S (2008). Targseting of microRNAs for therapeutics. Biochem 36: 1197-1200.
5. Brodersen, P and Voinnet, O (2009). Revisiting the principles of microRNA target recognition and mode of action. Nat Rev Mol Cell Biol 10: 141-148.
6. Stenvang, J and Kauppinen, S (2008). MicroRNAs as targets for antisense-based therapeutics. Expert Opin Biol Ther 8: 59-81.
7. Lennox, KA and Behlke, MA (2011). Chemical modification and design of anti-miRNA oligonucleotides. Gene Ther 18: 1111-1120.
8. Gao, S, Dagnaes-Hansen, F, Nielsen, EJ, Wengel, J, Besenbacher, F, Howard, KA et al. (2009). The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol Ther 17: 1225-1233.
9. Petersen, M, Nielsen, CB, Nielsen, KE, Jensen, GA, Bondensgaard, K, Singh, SK et al. (2000). The conformations of locked nucleic acids (LNA). J Mol Recognit 13: 44-53.
10. Wengel, J, Vester, B, Lundberg, LB, Douthwaite, S, Sørensen, MD, Babu, BR et al. (2003). LNA and alpha-L-LNA: towards therapeutic applications. Nucleosides Nucleotides Nucleic Acids 22: 601-604.
11. Kaur, H, Babu, BR and Maiti, S (2007). Perspectives on chemistry and therapeutic applications of Locked Nucleic Acid (LNA). Chem Rev 107: 4672-4697.
12. Crinelli, R, Bianchi, M, Gentilini, L and Magnani, M (2002). Design and characterization of decoy oligonucleotides containing locked nucleic acids. Nucleic Acids Res 30: 2435-2443.
13. Moschos, SA, Frick, M, Taylor, B, Turnpenny, P, Graves, H, Spink, KG et al. (2011). Uptake, efficacy, and systemic distribution of naked, inhaled short interfering RNA (siRNA) and locked nucleic acid (LNA) antisense. Mol Ther 19: 2163-2168.
14. Lanford, RE, Hildebrandt-Eriksen, ES, Petri, A, Persson, R, Lindow, M, Munk, ME et al. (2010). Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327: 198-201.
15. Garzon, R, Marcucci, G and Croce, CM (2010). Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 9: 775-789.
16. Teissie, J, Golzio, M and Rols, MP (2005). Mechanisms of cell membrane electropermeabilization: a minireview of our present lack of knowledge. Biochim Biophys Acta 1724: 270-280.
17. Cemazar, M, Golzio, M, Escoffre, JM, Couderc, B, Sersa, G and Teissié, J (2006). In vivo imaging of tumor growth after electrochemotherapy with cisplatin. Biochem Biophys Res Commun 348: 997-1002.
18. Cemazar, M, Golzio, M, Sersa, G, Hojman, P, Kranjc, S, Mesojednik, S et al. (2009). Control by pulse parameters of DNA electrotransfer into solid tumors in mice. Gene Ther 16: 635-644.
19. Gothelf, A, Mir, LM and Gehl, J (2003). Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat Rev 29: 371-387.
20. Sersa, G, Miklavcic, D, Cemazar, M, Rudolf, Z, Pucihar, G and Snoj, M (2008). Electrochemotherapy in treatment of tumours. Eur J Surg Oncol 34: 232-240.
21. Matthiessen, LW, Chalmers, RL, Sainsbury, DC, Veeramani, S, Kessell, G, Humphreys, AC et al. (2011). Management of cutaneous metastases using electrochemotherapy. Acta Oncol 50: 621-629.
22. Daud, AI, DeConti, RC, Andrews, S, Urbas, P, Riker, AI, Sondak, VK et al. (2008). Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 26: 5896-5903.
23. Golzio, M, Rols, MP and Teissié, J (2004). In vitro and in vivo electric fieldmediated permeabilization, gene transfer, and expression. Methods 33: 126-135.
24. Paganin-Gioanni, A, Bellard, E, Escoffre, JM, Rols, MP, Teissié, J and Golzio, M (2011). Direct visualization at the single-cell level of siRNA electrotransfer into cancer cells. Proc Natl Acad Sci USA 108: 10443-10447.
25. Chang, TC, Wentzel, EA, Kent, OA, Ramachandran, K, Mullendore, M, Lee, KH et al. (2007). Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 26: 745-752.
26. Raver-Shapira, N, Marciano, E, Meiri, E, Spector, Y, Rosenfeld, N, Moskovits, N et al. (2007). Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 26: 731-743.
27. Bommer, GT, Gerin, I, Feng, Y, Kaczorowski, AJ, Kuick, R, Love, RE et al. (2007). p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 17: 1298-1307.
28. Corey, DR (2007). Chemical modification: the key to clinical application of RNA interference? J Clin Invest 117: 3615-3622.
29. Stenvang, J, Silahtaroglu, AN, Lindow, M, Elmen, J and Kauppinen, S (2008). The utility of LNA in microRNA-based cancer diagnostics and therapeutics. Semin Cancer Biol 18: 89-102.
30. Ørom, UA, Kauppinen, S and Lund, AH (2006). LNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene 372: 137-141.
31. Hampton, T (2011). Electric pulses help with chemotherapy, may open new paths for other agents. JAMA 305: 549-551.
32. Golzio, M, Teissie, J and Rols, MP (2002). Direct visualization at the single-cell level of electrically mediated gene delivery. Proc Natl Acad Sci USA 99: 1292-1297.
33. Joergensen, M, Agerholm-Larsen, B, Nielsen, PE and Gehl, J (2011). Efficiency of cellular delivery of antisense peptide nucleic acid by electroporation depends on charge and electroporation geometry. Oligonucleotides 21: 29-37.
34. Belitsky, JM, Leslie, SJ, Arora, PS, Beerman, TA and Dervan, PB (2002). Cellular uptake of N-methylpyrrole/N-methylimidazole polyamide-dye conjugates. Bioorg Med Chem 10: 3313-3318.
35. Braasch, DA, Liu, Y and Corey, DR (2002). Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design. Nucleic Acids Res 30: 5160-5167.
36. Wahlestedt, C, Salmi, P, Good, L, Kela, J, Johnsson, T, Hökfelt, T et al. (2000). Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc Natl Acad Sci USA 97: 5633-5638.
37. Corsten, MF, Miranda, R, Kasmieh, R, Krichevsky, AM, Weissleder, R and Shah, K (2007). MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas. Cancer Res 67: 8994-9000.
38. Takeshita, F, Gursel, I, Ishii, KJ, Suzuki, K, Gursel, M and Klinman, DM (2004). Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9. Semin Immunol 16: 17-22.
39. Heil, F, Hemmi, H, Hochrein, H, Ampenberger, F, Kirschning, C, Akira, S et al. (2004). Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303: 1526-1529.
40. Koppelhus, U, Awasthi, SK, Zachar, V, Holst, HU, Ebbesen, P and Nielsen, PE (2002). Cell-dependent differential cellular uptake of PNA, peptides, and PNA-peptide conjugates. Antisense Nucleic Acid Drug Dev 12: 51-63.
41. Wanunu, M, Dadosh, T, Ray, V, Jin, J, McReynolds, L and Drndic, M (2010). Rapid electronic detection of probe-specific microRNAs using thin nanopore sensors. Nat Nanotechnol 5: 807-814.
42. Lam, AP and Dean, DA (2010). Progress and prospects: nuclear import of nonviral vectors. Gene Ther 17: 439-447.
43. Bergan, R, Hakim, F, Schwartz, GN, Kyle, E, Cepada, R, Szabo, JM et al. (1996). Electroporation of synthetic oligodeoxynucleotides: a novel technique for ex vivo bone marrow purging. Blood 88: 731-741.
44. Pichon, C, Freulon, I, Midoux, P, Mayer, R, Monsigny, M and Roche, AC (1997). Cytosolic and nuclear delivery of oligonucleotides mediated by an amphiphilic anionic peptide. Antisense Nucleic Acid Drug Dev 7: 335-343.
45. Marcusson, EG, Bhat, B, Manoharan, M, Bennett, CF and Dean, NM (1998). Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipids before entering the nucleus. Nucleic Acids Res 26: 2016-2023.
46. Leonetti, JP, Mechti, N, Degols, G, Gagnor, C and Lebleu, B (1991). Intracellular distribution of microinjected antisense oligonucleotides. Proc Natl Acad Sci USA 88: 2702-2706.
47. Zhang, Y, Qu, Z, Kim, S, Shi, V, Liao, B, Kraft, P et al. (2011). Down-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonucleotides without transfection. Gene Ther 18: 326-333.
48. Naguibneva, I, Ameyar-Zazoua, M, Nonne, N, Polesskaya, A, Ait-Si-Ali, S, Groisman, R et al. (2006). An LNA-based loss-of-function assay for micro-RNAs. Biomed Pharmacother 60: 633-638.
49. He, X, He, L and Hannon, GJ (2007). The guardian's little helper: microRNAs in the p53 tumor suppressor network. Cancer Res 67: 11099-11101.
50. Boyd, SD (2008). Everything you wanted to know about small RNA but were afraid to ask. Lab Invest 88: 569-578.